Neuroplasticity Associated with Extended Daily Use of a Sensorimotor Priming Vibration System to Improve Hand Function After Stroke Save

Date Added
March 5th, 2019
PRO Number
Pro00086207
Researcher
Na jin Seo

List of Studies


Profiles_link
Keywords
Aging, Central Nervous System, Movement Disorders, Muscle, Nerve, Nervous System, Physical Therapy, Rehabilitation Studies, Stroke, Stroke Recovery
Summary

The objective is to determine if continuous use of TheraBracelet in the home has a clinically meaningful effect in chronic stroke survivors. The study design is a double-blinded randomized controlled trial. We will enroll 40 chronic stroke survivors with moderate hand impairment. Subjects will be randomly assigned to the treatment or control group (n=20 per group). All subjects will wear the TheraBracelet device on the paretic wrist for 8 hours/day every day during their normal daily activity for 1 month. The device will deliver vibration (treatment) or no vibration (control). Double-blinding is possible because the treatment vibration is imperceptible (i.e., subthreshold). Measures of neural plasticity, the amount of the paretic arm use in daily living, clinical hand function, biomechanical grip control, and self-reported abilities for activities of daily living will be assessed at baseline, once a week during the month of wearing the device, and for 3-month follow-up, allowing determination of the efficacy and persistence.

Institution
MUSC
Recruitment Contact
Amanda Vatinno
843-792-8970
vatinno@musc.edu

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness Save

Date Added
January 22nd, 2019
PRO Number
Pro00084665
Researcher
Katherine Ruzhansky

List of Studies

Silhouette
Keywords
Muscle, Nervous System
Summary

Patients who have been diagnosted with Myasthenia Gravis having generalized muscle weakness may qualify to participate in this study.

Subjects that volunteer to participate will undergo a screening visit to assess their health. The purpose of the screening visit is to determine if the requirements to take part in this study are met. If you meet all of the requirements, you will be randomly assigned (like the flip of a coin) to either the study drug that is being researched called ARGX-113 or a placebo treatment group. You will have a one in two chance of being placed in either group. Neither you nor your study doctor will know what group you will be in. If you are in the placebo group, you will receive a substance that looks like ARGX-113 but contains no active medication. This is called a placebo. During the study, both treatment groups will be given the ARGX-113 or placebo through a vein in their arm, called an infusion. Participants will continue to take their current medicines for gMG.

The trial will include a Screening period of a maximum of 2 weeks, a first Treatment Cycle and a maximum of 2 of subsequent Treatment Cycles given on an "as needed basis". Each Treatment Cycle has 9 visits over 8 weeks consisting of a Treatment period of 4 weekly infusions and a Follow-up period of 5 weeks. There are also Inter-treatment Cycle Visits every 2 weeks between Treatment Cycles. The study will last for approximately 28 weeks, and qualified participants will need to come to MUSC at least 19 times over this period.

Institution
MUSC
Recruitment Contact
Katrina Madden
843-792-9186
maddenka@musc.edu

Title: Rapid Reversal of CNS-Depressant Drug Effect prior to Brain Death Determination Investigators: Sameh Hanna, MD, Justin Atwood, MD Institution: Palmetto Health-University of South Carolina Medical Group, Division of Pulmonary, Critical Care and Sleep Medicine, Columbia, SC Save

Date Added
December 11th, 2018
PRO Number
Pro00077995
Researcher
Sameh Hanna

List of Studies

Keywords
Brain, Central Nervous System, Nervous System
Summary

Prospective trial with enrollment of 30 patients in various intensive care units at Palmetto Health Richland from January 1st 2019 to June 30th 2020. If patients had undergone targeted temperature management (33-36 degrees Celsius for 24 hours via intravascular or surface control methods, with or without sedation or neuromuscular blockade, followed by rewarming actively or passively at 0.25-0.5 degrees per hour over 8-12 hours to 37 degrees) investigators will wait 24 hours after rewarming prior to testing. End point is to evaluate if pharmacological reversal agents would result in improved GCS scores or return of cerebral or brainstem functions in some comatose patients, which will be considered a positive test result.

Institution
Palmetto
Recruitment Contact
Sameh Hanna
8643443439
sameh.hanna@palmettohealth.org

Odor Disturbances: Clinical Care Registry Save

Date Added
September 26th, 2018
PRO Number
Pro00080333
Researcher
Thomas Uhde

List of Studies


Profiles_link
Keywords
ADD/ADHD, Adolescents, Aging, Allergy, Alzheimers, Anxiety, Asthma, Autism, Autoimmune disease, Central Nervous System, Chronic Fatigue, Depression, Environmental Factors, Fibromyalgia, Inflammation, Memory Loss, Nervous System, Parkinsons, Psychiatry
Summary

Candidates for this study may or may not report disturbances in odor perception as their primary reason for seeking treatment at MUSC. This study is designed to collect long term, observational data from patients who are being treated with routine clinical care in health clinics at MUSC. Data from clinical questionnaires will be de-identified and stored in a database.

Institution
MUSC
Recruitment Contact
Richard Simmons
843-792-7439
simmr@musc.edu

PROMISE-MG: Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-Modifying Treatments for Myasthenia Gravis Save

Date Added
September 24th, 2018
PRO Number
Pro00077927
Researcher
Katherine Ruzhansky

List of Studies

Silhouette
Keywords
Muscle, Nervous System
Summary

This is an observational study to develop a research registry to collect information from subjects with Myasthenia Gravis (MG) to evaluate the effects of the treatments they receive and to understand how their medical condition and treatment affects their daily life.

Institution
MUSC
Recruitment Contact
Katrina Madden
843-792-9186
maddenka@musc.edu

Direct measurement of motor cortical responses to transcranial direct current stimulation Save

Date Added
May 15th, 2018
PRO Number
Pro00073545
Researcher
Nathan Rowland

List of Studies

Silhouette
Keywords
Brain, Central Nervous System, Movement Disorders, Muscle, Nerve, Nervous System, Parkinsons, Surgery
Summary

Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with motor deficits, however its effects have not been consistent in randomized studies to date, limiting widespread adoption of this technology. A critical gap in our knowledge is a detailed understanding of how tDCS affects motor areas in the brain. We propose using tDCS while recording directly from motor cortex using subdural electrocorticography (sECoG) in patients undergoing deep brain stimulation surgery. We expect this novel approach to broaden our understanding of tDCS application and possibly lead to therapeutic advances in this population.

Institution
MUSC
Recruitment Contact
Sanicqua Robinson Smalls
843-792-8553
robinsst@musc.edu

Transcranial magnetic stimulation for modulation of postural control in progressive supranuclear palsy Save

Date Added
April 17th, 2018
PRO Number
Pro00076691
Researcher
Marian Dale

List of Studies

Silhouette
Keywords
Central Nervous System, Geriatrics, Movement Disorders, Nervous System, Rare Diseases, Rehabilitation Studies
Summary

This research studies the effects of brain stimulation (transcranial magnetic stimulation, or "TMS") on balance in progressive supranuclear palsy (PSP). The purpose of this research is to look for improvements in balance when subjects are on a tilting platform after stimulating the brain with a magnetic wand held over the scalp over an area at the back of the brain called the cerebellum. Participants will receive both active and inactive stimulation during the course of the study. There is no surgery involved. There are also optional portions of the study that include functional magnetic resonance imaging (fMRIs) and speaking samples.

Institution
MUSC
Recruitment Contact
Shonna Jenkins
843-792-9115
jenkisho@musc.edu

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard-of-Care Study of n-Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Acute Ischemic Stroke in Adult Subjects Save

Date Added
February 22nd, 2018
PRO Number
Pro00073072
Researcher
Souvik Sen

List of Studies

Keywords
Brain, Nervous System, Stroke, Vascular
Summary

This study will assess patients with acute ischemic strokes being treated with n-Butylphthalide (NBP) softgel capsules. This is a phase II study to evaluate the safety of NBP treatment. The medication has the potential to reduce impairment of memory function, cerebral edema, and disruption of the blood-brain barrier.

Institution
Palmetto
Recruitment Contact
Viktoriya Duda
(803)545-6071
viktoriya.duda@uscmed.sc.edu

Realistic measurements of tDCS-modulated activity and electric fields in the human brain in vivo Save

Date Added
September 19th, 2017
PRO Number
Pro00069308
Researcher
Pratik Chhatbar

List of Studies

Silhouette
Keywords
Brain, Epilepsy, Nervous System
Summary

In this study, we will use electrodes implanted inside the skull and over the scalp to study the effect of non-invasive brain stimulation method called transcranial direct current stimulation (tDCS). We will record changes in electric brain potentials and brain activity as a result of tDCS at both inside skull at scalp level. We will use this information to interpret how tDCS leads to changes inside the brain leading to changes the brain activity. This study will help us develop interventions that involve use of tDCS in a variety of disease conditions like stroke, depression, addiction, etc.

Institution
MUSC
Recruitment Contact
Fay Davis
843-792-0883
davisfa@musc.edu

Validation of computer-based saccade and pupillary light reflex measures as biomarkers for progressive supranuclear palsy Save

Date Added
July 18th, 2017
PRO Number
Pro00065862
Researcher
Marian Dale

List of Studies

Silhouette
Keywords
Aging, Brain, Movement Disorders, Nervous System, Parkinsons, Rare Diseases, Vision/ Eye
Summary

This study examines eye movements and the pupil's response to light in progressive supranuclear palsy (PSP), comparing to Parkinson's disease and control subjects without neurological disease. Computerized measures of eye movements and pupil changes will be used. Subjects will also receive an eye exam to rule out other eye diseases. The goal of this study is to use subtle changes in eye movements and the pupil's response to light for earlier diagnosis of PSP.

Institution
MUSC
Recruitment Contact
Shonna Jenkins
843-792-9115
jenkisho@musc.edu

Change_preferences

-- OR --

Create_login